Logo Logo Logo Logo Logo
  • COMPANY
    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us
  • SCIENCE
    • OPTIREACH Technology
    • Antibody Fragment Technology
    • Neuroprotective approach for eye diseases
    • Publications
  • PIPELINE
    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 Acute Optic Neuritis
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources

  • COMPANY

    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us

  • SCIENCE

    • OPTIREACH Technology
    • Antibody Fragment Technology
    • Neuroprotective approach for eye diseases
    • Publications

  • PIPELINE

    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 Acute Optic Neuritis
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources
Contact us

Oculis Holding AG

Bahnhofstrasse 7
6300 Zug
Switzerland

+41 58 810 0182

 

info@oculis.com

Copyright © 2023 Oculis

 

Oculis SA

EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne – Switzerland

+41 21 711 3970

    © Oculis – Privacy Policy – Terms of Use  – Cookie Policy    

    © L’autreagence 2019 – 2023